Trending Sources

How the Hell do I Prioritize Work, Blog & Find Balance?

Both Sides of the Table

I don’t know Ezra yet but since he’s taking the time to blog (which I hugesly respect) and share thoughts I thought I’d take him up on his challenge and also spill the beans on my secrets. On blogging I blog because I love it. My other secret on blogging?

Entrepreneurshit. The Blog Post on What It’s Really Like.

Both Sides of the Table

It’s 4.50am. Sunday morning. And I couldn’t sleep. I have much on my mind since I just returned from a week on the road. 5 days. 3 cities. Late night Mexican food. Beers. Airports. Delays. I left on a Sunday. I had to miss a full day with my family, camping in the mountains.

HipGeo Launches Updated iPhone Travel Blogging App

socalTECH

The company said the redesign came after finding that users were interested in using its tools to create blog-like travel and trip journals, rather than the original, animated slideshows the tool provided. networking social blogging travel iphone hipgeo

Blogging for the Hell of It, Not Blogging to Stay Relevant

Both Sides of the Table

I used to love blogging. Blogging proved to be a great way to hone my ideas, have public conversations with people and as it turns out – build meaningful relationships through public dialog that spilled over into the real world. Somewhere along the way blogging changed. Fred Wilson said as much in his blog post today, too. I guess it’s just a reality of blogging and I accept that. I like “single take” blogging.

VC Confidence Holds Steady in Quarterly Survey, But Reasons Change

Xconomy

Proofpoint Uncovers Second Cyberattack That Uses Stolen NSA Tools

Xconomy

Cybersecurity company Proofpoint, which helped slow the sweeping global ransomware attack WannaCry after it emerged Friday, has now discovered a much more insidious, profitable, and potentially widespread cyberattack called Adylkuzz. Adylkuzz doesn’t demand, as WannaCry does, that victims pay a ransom to retrieve their data. Adylkuzz makes no announcement when it quietly invades target computers.

Gottlieb Reportedly On Tap to Lead FDA, and Biopharma Exhales

Xconomy

According to several news reports, the Trump administration will nominate Scott Gottlieb to be the new commissioner of the FDA, a selection that had the life sciences industry breathing a sigh of relief Friday afternoon.

News 34

Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed?

Xconomy

It’s a struggle that comic-book fans know well. Ordinary people, bestowed with super powers from a spider bite or gamma rays, struggle to harness their own abilities. T cells, key soldiers of the immune system, are wrestling with new-found super powers, too.

Toyota And Others Enabling Self-Driving Cars to Talk to Each Other

Xconomy

Drivers have plenty of ways to communicate with their fellow drivers, beyond the basic turn signal. Some methods are nice, like a friendly wave to beckon a merging car into your lane. Others, not so much. We’ve all probably cursed or honked at another driver, or been given the finger.

Report: Biotech VCs Perpetuate Boardroom Gender Gap

Xconomy

If power in the business world is centered in the boardroom, women in biotech have a long way to go to get their fair share—and the venture community deserves much of the blame.

Study 32

7 Ways to Secure Your Connected Devices Against Hackers

Xconomy

’Tis the season for giving gifts. And increasingly, those shiny new toys and gadgets can be connected to the Internet—from TVs to watches, speakers to Barbie dolls. That Internet connection opens up a ton of possibilities for how we can use and enjoy our new devices.

Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More

Xconomy

Boston blog main Boulder/Denver blog main Detroit blog main Indiana blog main National National blog main New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Adynxx Allergan Amgen Anokion ARCH Venture Partners Ariad Pharmaceuticals Assembly Biosciences Biogen Biotech CureVac deals Donald Trump Ed Kaye Eteplirsen Exondys 51 FDA gender diversity George Scangos Hill-Rom Holdings J.P.

Sluggish Year for IPOs, But Signs Abound of Post-Election Surge

Xconomy

Uncertainty surrounding this year’s presidential election has kept U.S. IPO activity at a sluggish pace—so sluggish, in fact, that this year could end with the fewest IPOs and the lowest level of capital raised since 2009, according to PitchBook data for the first nine months of 2016.

Despite Low Crop Prices, Corporate and VC Agtech Investments Soar

Xconomy

Prices for agricultural commodities such as corn, soy, and wheat are at their lowest levels in years, but investment in agricultural technology has never been better.

Biotech Leaders Sign Letter Condemning Trump’s Travel Ban

Xconomy

The blowback from U.S. business leaders to President Trump’s travel ban continues—today from a throng of biotech executives. This morning, 165 U.S. biotech leaders have signed a letter voicing “deep concern and opposition” to the order, which bars entry to the U.S. to refugees and immigrants from seven Muslim-majority countries. The Jan. 27 order placed a 90-day ban on immigrants from Iraq, Iran, Syria, Sudan, Somalia, Libya, and Yemen.

Bio Roundup: Big Apple Mo’, Checkpoint Yes and No, CAR-T Death & More

Xconomy

“New York, New York, it’s a hell of a town. The Bronx is up, but we’re Brooklyn down.” ” For all you old-school Brooklyn swingers out there, we’ll take a short break from the madness in the nation’s capital and start our roundup in the greatest city in the world. You might disagree if you’ve got biotech dreams.

Bio Roundup: Termeer Tribute, ASCO Peeks, Califf’s New Gigs & More

Xconomy

Exhausted by the nonstop drama in Washington, DC? Immerse yourself instead in this week’s biotech headlines. Let’s start with a tribute to a life sciences icon, then we’ll head around the Xconomy network with early news from the nation’s big yearly cancer meeting. There was also momentum onthe IPO front and new gigs for high-profile folks (with just one stop on Capitol Hill along the way, we promise). Let’s get right to it.

News 15

Seed-Stage Deals Show Growing Diversity of Agtech Investments

Xconomy

Fundraising is tough for startups but it’s particularly difficult in agriculture, a sector that has fewer firms focused on agtech investments. The dynamics are starting to change, though.

Should You Bother Targeting the Tech Blogs for Your PR Campaigns?

Both Sides of the Table

6 or 7 years ago when TechCrunch was at its peak market share (they are still strong but many more tech blogs have also popped up) there was a term for getting covered there called “the TechCrunch bounce.” that they probably read the main tech blogs.

Bio Roundup: NIH Precision Boost, AHCA to Senate, New Drugs & More

Xconomy

Two dramatic healthcare stories played out this week. First, to the jubilation of the nation’s science community, Congress proposed to boost National Institutes of Health funding, not slash it as the Trump administration had outlined.

Bio Roundup: Travel Ban, Pharma in D.C., Biogen Splits, PCSK9 Wins

Xconomy

Folks had just clocked out last Friday when the Trump Administration announced a travel ban that threw airports around the country into chaos. That announcement set the tone for this week in life sciences. Many in biopharma blasted Trump’s order and tried to grapple with its implications.

At Big Hemophilia Meeting, More Data, and Promise, For Gene Therapy

Xconomy

Kentucky Biotech CEO’s Message For McConnell: I’ll Be Muslim, Too

Xconomy

President Trump’s order to bar refugees and immigrants from seven Muslim-majority countries is on temporary hold, and a court hearing later today could eventually force a ruling by the U.S. Supreme Court. One of the latest biotech executives to speak out against the ban is in the backyard of Mitch McConnell (R-KY), the top Republican in the U.S. Senate.

AACR Review: Biden Fired Up, Incyte Doubles Up, BMS Up And Down

Xconomy

The American Association for Cancer Research held its annual meeting this week in Washington, DC, a convenient venue for former Vice President Joe Biden to deliver a broadside against the Trump administration’s proposed budget cuts in science funding. For Biden, it’s personal.

Ex-Xerox CTO Vandebroek Named Chief Operating Officer of IBM Research

Xconomy

Boston Boston blog main Boston top stories Boulder/Denver blog main Detroit blog main Indiana blog main National blog main National top stories New York blog main New York top stories Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Cognitive Computing Conduent Cybersecurity Healthcare IT Healthtech IBM IBM Research Internet of Everything IoE IoT people R&D Sophie Vandebroek Xerox

Interesting New Tech Blog for your Radar Screen

Both Sides of the Table

Over the holiday I became aware of a new tech blog that aims to have deep insights into the next generation of technology, which they call The Hypernet.

Aira Raises $12M to Expand Services for Blind and Visually Impaired

Xconomy

Boston blog main Detroit blog main National blog main National top stories San Diego San Diego blog main San Diego top stories San Francisco blog main Texas blog main Aira Aira.io After beta testing technology that provides remote assistant services for the blind, San Diego-based Aira has raised $12 million in a Series B round that it says will enable the company to expand its service to thousands of visually impaired users this year.

Guide 26

Biopharma Leaders Call for Gender Diversity Amid J.P. Morgan Conference

Xconomy

A group of more than 100 prominent life sciences executives, investors, and business leaders have signed an open letter calling on the industry to step up efforts to increase gender diversity. The letter was published Wednesday , on the second to last day of the annual J.P.

Bio Roundup: New Drug Bonanza, Vertex’s Triple Play, CAR-T Race & More

Xconomy

As far as singular weeks go for biotech, this was a big one. Three highly anticipated drugs were approved. One is the first injectable medication for eczema. Another might help fend off the recurrence of ovarian cancer. And a third offers hope for people with severe forms of multiple sclerosis. Another drug, a new combination therapy for cystic fibrosis, could follow this year after succeeding in two large tests. Each drug might help change how these diseases will be treated for years to come.

14 for ’17: Key Clinical Data To Watch For Next Year (Part 2)

Xconomy

We continue our look ahead to some of the clinical data due in 2017 that could shape healthcare practice and sway investor sentiment for years to come. Part one of our preview is here , with looks at key studies in lung cancer, Alzheimer’s disease, asthma, and more. In part two, we examine studies in leukemia, migraine, multiple sclerosis, Parkinson’s disease, postpartum depression, amyloidosis, and Zika virus vaccine.

Bio Roundup: Trumpcare Wavers, Amgen Courts Payers, Critics Circle PTC

Xconomy

Who knew healthcare could be so complicated ? This week, President Trump and the GOP saw first hand, as a feverish rally to get their healthcare bill through the House of Representatives on Thursday stalled before a vote. Elsewhere in Washington DC, drug pricing continued to be a political football.

Bio Roundup: CRISPR Appeal, Bristol Deals, Stock Pumping & More

Xconomy

It may have been a short holiday week, but there was plenty of news on the CRISPR front. In the ongoing battle for rights to the landmark gene editing technology, the faction led by the University of California appealed the U.S. decision in favor of the Broad Institute. Elsewhere, Bristol-Myers Squibb flipped assets, a top dealmaker made an unexpected tack into the perilous waters of Alzheimer’s drug development, and the SEC cracked down on stock pumping schemes. Let’s round it all up.

Immunotherapy Clinical Tests Spur Hope, and Plenty of Headaches

Xconomy

Thanks to remarkable results in a small group of patients, including former U.S. President Jimmy Carter , cancer immunotherapy has spurred talk of once impossible-to-imagine cures and has gained its share, perhaps more than its share, of hype.

Study 36